The Dendritic Cell Receptor DNGR-1 Promotes the Development of Atherosclerosis in Mice. by Haddad, Yacine et al.
DOI: 10.1161/CIRCRESAHA.117.310960   1 
The Dendritic Cell Receptor DNGR-1 Promotes the Development of Atherosclerosis in 
Mice  
Yacine Haddad1, Charlotte Lahoute1, Marc Clément2, Ludivine Laurans1, Sarvenaz Metghalchi1, Lynda 
Zeboudj1, Andreas Giraud1, Xavier Loyer1, Marie Vandestienne1, Julien Wain-Hobson1, Bruno Esposito1,
Stephane Potteaux1, Hafid Ait-Oufella1, Alain Tedgui1, Ziad Mallat1, 2, Soraya Taleb1 
1Institut National de la Santé et de la Recherche Médicale (Inserm), Unit 970, Paris Cardiovascular 
Research Center, and Université Paris-Descartes, Paris, France, and ; 2Division of Cardiovascular 
Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 2QQ, UK. 
Running title:  CD8α+ Dendritic Cells, IL-10 and Atherosclerosis 
Subject Terms: 
Atherosclerosis 
Address correspondence to:  
Dr. Ziad Mallat 
Cardiovascular Medicine 
 University of Cambridge 
Addenbrooke's Hospital 
Cambridge, CB2 2QQ 
United Kingdom 
zm255@medchl.cam.ac.uk 
Dr. Soraya Taleb 
INSERM 970 
Paris Cardiovascular Research Center  
Paris, France 
soraya.taleb@inserm.fr 
In May 2017, the average time from submission to first decision for all original research papers submitted to 
Circulation Research was 12.28 days.
DOI: 10.1161/CIRCRESAHA.117.310960   2 
ABSTRACT 
Rationale: Necrotic core formation during the development of atherosclerosis is associated with a chronic 
inflammatory response and promotes accelerated plaque development and instability. However, the 
molecular links between necrosis and the development of atherosclerosis are not completely understood. 
C-type lectin receptor (Clec9a) or DNGR1 is preferentially expressed by the CD8α+ subset of dendritic 
cells (CD8α+DCs) and is involved in sensing necrotic cells. We hypothesized that sensing of necrotic cells 
by DNGR1 plays a determinant role in the inflammatory response of atherosclerosis. 
Objective: We sought to address the impact of either total, bone marrow (BM) or CD8α+ DC-restricted 
deletion of DNGR1 on atherosclerosis development. 
Methods and Results: We show that total absence of DNGR1 in apolipoprotein e-deficient mice (Apoe-/-) 
mice as well as BM-restricted deletion of DNGR1 in low-density lipoprotein receptor-deficient (Ldlr-/-) 
mice significantly reduce inflammatory cell content within arterial plaques and limit atheroslerosis 
development in a context of moderate hypercholesterolemia. This is associated with a significant increase 
of the expression of interleukin 10 (IL10). The atheroprotective effect of DNGR1 deletion is completely 
abrogated in the absence of BM-derived IL10. Furthermore, a specific deletion of DNGR1 in CD8α+ DCs 
significantly increases IL10 expression, reduces macrophage and T cell contents within the lesions, and 
limits the development of atherosclerosis.  
Conclusions: Our results unravel a new role of DNGR1 in regulating vascular inflammation and 
atherosclerosis, and potentially identify a new target for disease modulation. 
Keywords:  
DNGR1, IL-10, CD8α+dendritic cells, atherosclerosis, inflammation, necrosis. 
Nonstandard Abbreviations and Acronyms: 
Apoe-/- apolipoprotein e-deficient mice 
BM  bone marrow  
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DNGR-1 Dendritic cell NK lectin Group Receptor-1 
HFD high fat diet  
Ldlr-/- low-density lipoprotein receptor-deficient 
MERTK  myeloid-epithelial-reproductive tyrosine kinase  
MFGE8  milk fat globule EGF-like Factor 8  
PRR  pattern recognition receptors  
SYK spleen tyrosine kinase  
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INTRODUCTION 
Accumulation of apoptotic cells and necrotic debris within the lipid core is a major feature of 
advanced atherosclerotic lesions and has been associated with increased susceptibility to thrombotic 
complications following plaque rupture 1-4. We and others have shown that accumulation of apoptotic and 
secondary necrotic debris in atherosclerotic lesions results from defective efferocytosis or clearance of 
apoptotic cells3-5. This in turn leads to activation of immune-inflammatory responses and accelerates the 
progression of atherosclerosis 3, 5, 6. Mouse models of decreased efferocytosis, such as mice lacking the 
receptor myeloid-epithelial-reproductive tyrosine kinase (MERTK) or the bridging molecule milk fat 
globule EGF-like Factor 8 (MFGE8) showed an alteration of the protective immune response, associated 
with increased vascular inflammation and enhanced necrotic core formation 7 , 8 , 9. However, the 
mechanisms involved in necrosis-induced inflammation during atherosclerosis development are not fully 
understood.  
Dying cells release endogenous molecules known as damage-associated molecular patterns 
(DAMPs) that are recognized by pattern recognition receptors (PRR) in immune cells. Toll-like receptors 
(TLRs) and C-type lectin receptors (CLRs) are 2 main PRR families expressed on immune cells, including 
macrophages and dendritic cells (DCs). Dendritic cell NK lectin Group Receptor-1 (DNGR-1), also known 
as CLEC9a, is a type II transmembrane CLR containing a single extracellular C-type lectin-like domain 
and a cytoplasmic tail with a hemi-immunoreceptor tyrosine-based activation motif that allows 
recruitment/activation of the spleen tyrosine kinase (SYK) pathway 10, 11. DNGR1 is mostly expressed by 
the CD8α+ subset of dendritic cells (CD8α+DCs) as a receptor for necrotic cells, which favors cross-priming 
of cytotoxic T-lymphocytes to dead cell-associated antigens in mice 11. Although this receptor is not 
essential for particle uptake via phagocytosis 11, DNGR1 is capable of internalizing bound antigens via 
endocytosis and directing them to the endosomal vesicles for cross-presentation of dead cell associated 
antigens by CD8α+ DCs 12, 13. 
Our hypothesis is that accumulation of apoptotic and necrotic debris during the development of 
atherosclerosis activates DNGR1, leading to disease progression. Here, we show that DNGR1 expression 
in hematopoietic cells and particularly in CD8α+DCs promotes atherosclerosis through down-regulation of 
the anti-inflammatory and anti-atherogenic cytokine, IL10.  
METHODS 
Detailed methods can be found in the online Data Supplement.  
Animals. 
Il10-/-, Apoe-/- and Ldlr–/– mice were from the Jackson Laboratory. C57BL/6 Clec9a-/- mice are from Reis e 
Sousa lab11. Clec9a-/- mice were backcrossed on C57Bl/6 for more than 10 generations. Littermates 
C57BL/6 Clec9a-/- and C57BL/6 Clec9+/+ were used in all the experiments. Briefly, these mice are 
Clec9agfp/gfp in which DNGR1 expression is abrogated by the insertion of a gene encoding a membrane-
anchored form of green fluorescent protein (GFP) into the Clec9a open reading frame11. CD8α+ DC-
deficient (Cd11cCre+/Irf8flox/flox)  mice were obtained by crossing Irf8flox/flox (Jax) with Cd11cCre+ (Jax). Mfge8-
/- mice were previously described 14. Apoe–/–Clec9a–/–, Clec9a-/-Il10-/- and Clec9a–/–Mfge8-/- mice were 
generated by crossing respectively Apoe-/- to Clec9a-/-, Il-10-/- to Clec9a-/- and Mfge8-/- to Clec9a-/- mice. 
Apoe-/- and Apoe-/-Clec9a-/- male mice on either chow diet (20 weeks) or high fat diet (HFD) (6 weeks) were 
used in some experiments. We subjected seven to 10-week-old Ldlr–/–male mice to medullar aplasia by 9.5 
gray lethal total body irradiation. We repopulated the mice with an intravenous injection of bone marrow 
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cells isolated from femurs and tibias of age- and sex-matched C57Bl/6J mice: Clec9a+/+, Clec9a–/–or Il10–/–
or Clec9a–/–Il10–/–or Mfge8-/- or Clec9a-/-Mfge8-/- mice. After 4 weeks of recovery, mice were fed with a 
proatherogenic diet containing 15% fat, 1.25% cholesterol, and 0% cholate for 5, 7 or 13 weeks.  
Finally, we irradiated Ldlr-/- mice and transplanted them with 2:8 mixture of either control (CD45.1) bone 
marrow or Clec9a-/- bone marrow mixed with bone marrow from CD8α+ DC-deficient (Cd11cCre+/Irf8flox/flox) 
mice. After 4 weeks of reconstitution, the mice were put on HFD diet for 7 weeks. 
All mice used in these experiments were bred and housed in a specific pathogen-free barrier facility. 
Experiments were conducted according to the French veterinary guidelines and those formulated by the 
European community for experimental animal use (L358-86/609EEC).  
Extent and plaque composition of atherosclerotic lesions. 
Quantification of lesion size and composition was performed as previously described15.  
Flow cytometry. 
Flow cytometry analysis was performed on single cell suspensions of spleen and peritoneal cells as 
mentioned before16.  
Cell recovery and stimulation. 
Cells were cultured in RPMI 1640 supplemented with Glutamax, 10% FCS, 0.02 mM 2-mercaptoethanol 
and antibiotics. Splenocytes were stimulated with LPS (1 g/ml) (Sigma) for 48 h and then supernatants 
were subjected to cytokine measurements. Spleen DCs, CD8α+DCs, CD8α-DCs, CD3+ and CD4+ T cells 
were purified using Miltenyi kits. To analyze cytokine production by T cell, 105 CD3+ or CD4+ T cells were 
cultured alone or co-cultured with 105 CD8α+ DCs in 96-well microplates (total volume 200 μl/well) pre-
coated overnight at 4°C with anti-CD3 antibody (5 μg/ml, Pharmingen) and anti-CD28 antibody (1 μg/ml, 
Pharmingen) during 48 h in presence of LPS (1 g/ml). Neutralizing anti-IL10 receptor antibody or control 
IgG (R&D Systems) and water-soluble cyclodextrin-cholesterol (Sigma) were used in some experiments. 
On supernatants, ELISAs were performed to measure IL10, IL17, TNFα, IL6 and IFNγ (BD) of the different 
conditions.  
Statistical analysis. 
Values are expressed as means ± s.e.m. Differences between values were examined using Student t-test. 
Mann Whitney is applied in the animal studies. Values were considered significant at P≤0.05. 
RESULTS 
DNGR1 deficiency decreases the development of atherosclerosis. 
To study the role of DNGR1 in atherosclerosis, we crossed Clec9a -/- mice with atherosclerosis-
susceptible Apoe-/- mice, and generated Apoe-/-Clec9a-/- mice and Apoe-/-Clec9a+/+ littermate controls. Both 
groups were put on chow diet until sacrifice at 20 weeks of age. As shown in Figure 1, invalidation of 
DNGR1 led to a marked 60 % decrease of plaque size (p=0.002), despite no significant change in plasma 
cholesterol levels (Figure 1A-C). We also reconstituted lethally-irradiated Ldlr-/- mice with Clec9a+/+ or 
Clec9a -/- bone marrow. After 4 weeks of recovery, mice were put on HFD for 5 or 7 weeks to study early 
disease stages, and for 13 weeks to study advanced stages of atherosclerosis. As expected, plasma 
cholesterol levels significantly increased overtime during HFD, without any significant differences between 
mice transplanted with Clec9a-/- or Clec9a+/+ bone marrow cells (Supplementary Fig. IA). Mice 
reconstituted with Clec9a-/- bone marrow showed significant reduction in atherosclerosis at the aortic sinus 
(Figure 1D and E) compared with mice reconstituted with Clec9a +/+ bone marrow after 5 or 7 weeks of 
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HFD, confirming the atheroprotective effect of DNGR1 deletion. Plaque area was also significantly 
decreased in the thoracic aorta after 7 weeks of HFD in mice reconstituted with Clec9a -/- compared to 
Clec9a +/+ bone marrow (Figure 1F). However, DNGR1 deletion in bone marrow-derived cells had no effect 
on atherosclerosis in mice fed HFD for 13 weeks (Figure 1D and E). Also, there was no difference in plaque 
size between Apoe-/-Clec9a+/+ and Apoe-/-Clec9a-/- mice fed a HFD during 6 weeks  (Supplementary Fig. IB 
and C). 
 
This was a surprising finding given that necrotic cores, which may activate signaling by DNGR1, 
show increased accumulation in lesions at the advanced stages of atherosclerosis (Supplementary Fig.ID). 
To account for that finding, we hypothesized that the absence of DNGR1 pro-atherogenic effects after 13 
weeks of HFD in Ldlr-/- mice or after HFD in Apoe-/- mice was due to the very high plasma cholesterol 
levels observed in these mice, rather than to the advanced stage of the plaques.  
 
We then examined Clec9a mRNA in the spleen, a tissue known to readily express Clec9a 17 and to 
play a major role in atherosclerosis 18 19. As shown in Supplementary Figure IIA, Clec9a chimerism was 
high at all time points (7 or 13 weeks), as assessed by the almost total absence of Clec9a expression in 
spleens of mice reconstituted with DNGR1-deficient bone marrow. However, Clec9a expression in spleens 
of Ldlr-/- mice reconstituted with Clec9a+/+ bone marrow markedly decreased after 13 weeks of HFD, 
compared with that of Ldlr-/- mice on chow diet or after 7 weeks of HFD (Supplementary Fig.IIA). This 
may suggest that Clec9a expression was down regulated by the prolonged and severe hypercholesterolemia 
after 13 weeks of HFD. Consistent with this hypothesis, in vitro incubation of splenocytes from Clec9aGfp/Gfp 
mice, in which the Clec9a gene was replaced by a GFP reporter gene (see Materials and Methods) in the 
presence of cholesterol markedly decreased GFP expression (Supplementary Fig. IIB). 
 
In order to investigate the role of Clec9a in advanced atherosclerosis whilst avoiding severe and 
prolonged hypercholesterolemia, we generated Clec9a -/-Mfge8-/- mice by crossing Mfge8-/- mice, in which 
the accumulation of late apoptotic/necrotic cells is increased due to defective efferocytosis 20, 21, with Clec9a 
-/- mice. Then, lethally-irradiated male Ldlr-/- mice were reconstituted with either Mfge8-/- or Clec9a -/-Mfge8-
/- bone marrow cells, and put on HFD for 7 weeks. As expected, a very small apoptotic area as assessed by 
TUNEL staining was detected in plaques of Ldlr-/-mice reconstituted with Clec9a +/+ or Clec9a -/- bone 
marrow at this early stage of disease development (Supplementary Fig. IIIA-B). As previously published 9, 
Mfge8 deficiency markedly increased apoptotic TUNEL+ area (Supplementary Fig. IIIA-B), and 
accelerated lesion development (Supplementary Fig. IIIC-D) under ‘moderate’ hypercholerolemia 
(5.01±0.66 g/L vs 5.86±0.45 g/L, p=0.33 in WT and Mfge8-/- mice, respectively). No significant changes of 
necrotic core area was observed between Clec9a -/-Mfge8-/-  and Mfge8-/- groups (data not shown). 
Interestingly, atherosclerotic lesion size in Ldlr-/- mice reconstituted with Mfge8 -/- bone marrow at 7 weeks 
of HFD was similar to that of Ldlr-/-mice fed a HFD for 13 weeks. Remarkably, Ldlr-/- mice transplanted 
with Clec9a -/-Mfge8-/- bone marrow showed a marked reduction of atherosclerosis (Supplementary Fig. 
IIIC-D) as compared with mice transplanted with Mfge8-/- bone marrow, despite no change in plasma 
cholesterol levels (5.86±0.45 g/L vs 6.19±0.33 g/L, p=0.56 in Mfge8-/- and Clec9a -/-Mfge8-/- mice, 
respectively). This indicates that DNGR1 promotes atherosclerosis even at advanced stages of lesion 
development, but only in a context of ‘moderate’ hypercholesterolemia. 
 
DNGR1 mediates pro-atherogenic effects through down-regulation of IL10. 
 
We next assessed lesion composition in Clec9a -/-  Ldlr-/- and Clec9a +/+  Ldlr-/- mice after 5, 7 
and 13 weeks of HFD. The percentage of macrophages (MOMA-2 staining/plaque surface) showed a 
significant decrease in mice reconstituted with DNGR1-deficient bone marrow after 5, 7 or 13 weeks of 
HFD, compared with chimeric Clec9a +/+ mice (Supplementary Fig. IVA). T lymphocyte accumulation 
within the lesions (CD3 staining) significantly decreased in mice transplanted with Clec9a -/-, compared to 
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Clec9a +/+ at 7 weeks of HFD (p=0.047) (Figure 2A), but this effect was lost at 13 wks of HFD (p= 
0.77)(Figure 2B) when plasma cholesterol levels were excessively high.  
 
We then examined the inflammatory profile in spleens of Ldlr-/-mice reconstituted with either 
Clec9a +/+or Clec9a -/- bone marrow. The expression of major inflammatory cytokines involved in 
atherosclerosis, including Ifnγ, Il1β and Il6 22 was not different between the 2 groups of mice after 7 weeks 
of HFD (Supplementary Fig. IVB). However, as shown in Supplementary Fig. VA-B and Figure 2C, 
DNGR1 deficiency after 5 and 7 weeks, but not after 13 weeks of HFD, markedly increased Tgfβ and Il10 
expression, suggesting an anti-inflammatory and anti-atherogenic phenotype 23-26. We also found a 
significant increase of IL10 production by splenocytes in the absence of DNGR1 after lipopolysaccharide 
(LPS)-TLR4 stimulation (Supplementary Figure VC), without significant changes in TNFα or IL6 (data not 
shown), suggesting that DNGR1 acts as a regulator of IL10. 
 
To directly address the physiological relevance of enhanced expression of IL10 by DNGR1- 
deficient bone marrow cells, we generated Clec9a -/-Il10-/- mice. We recovered bone marrow from Il10-/-or 
Clec9a -/-Il10-/- mice to reconstitute lethally-irradiated Ldlr-/-mice. After 4 weeks of recovery, mice were put 
on HFD for 7 weeks. As previously reported 27, IL10 deficiency in the bone marrow accelerated lesion 
development (Figure 3A-B), despite no change in plasma cholesterol levels (5.00 ±0.78 g/L vs 4.57±0.20 
g/L, p=0.93). Strikingly, the observed atheroprotective effect of Clec9a deficiency (see Figure 1D) was 
completely abolished in Clec9a -/-Il10-/-  Ldlr-/- mice, (Figure 3A-B), despite no impact on plasma 
cholesterol levels (4.57±0.20 g/L vs 4.81±0.20 g/L, p=0.53). Clec9a expression in Il10-/-  Ldlr-/- spleens 
is comparable to Il10+/+  Ldlr-/- indicating that inflammation is not involved in the modulation of Clec9a 
expression (data not shown). Moreover, no significant differences in necrotic core area, macrophage or T 
cell infiltration were observed between Ldlr-/-mice reconstituted with bone marrow cells from either Il10-/- 
or Clec9a -/- Il10-/- (Figure 3C-E). This data further demonstrate that the modulation of IL10 expression is 
an important mechanism through which DNGR1 mediates its pro-atherogenic effects. 
 
DNGR1 expressed in CD8α+ DCs regulates IL10 production and atherosclerosis development. 
 
DNGR1 is highly expressed in CD8α+ DCs 11. However, the role of CD8α+ DCs in atherosclerosis 
is still poorly understood 28, 29. To address the direct role of CD8α+ DC-specific DNGR1 in atherosclerosis, 
we used irradiated Ldlr-/- mice transplanted with a 8:2 mixture of CD8α+ DC-deficient (Cd11cCre+/Irf8flox/flox) 
(Supplementary Figure VIA) CD45.2 bone marrow (80%), mixed with either Clec9a +/+ (CD45.1) or Clec9a 
-/- bone marrow (20%). In these chimeric mice, at least 80% of spleen cells other than CD8α+ DCs, including 
T cells (CD4+ and CD8+), B cells (B220+), CD8α- DCs, macrophages (F4/80+) and neutrophils (GR1+), 
derived from the 80% Cd11cCre+/Irf8flox/flox (CD45.2) bone marrow (Supplementary Figure VIB and Figure 
4A). On the other hand, we expected all CD8α+ DCs to reconstitute almost exclusively from the 20% bone 
marrow (Clec9a +/+ or Clec9a -/-). In agreement with this, Clec9a mRNA was highly expressed in purified 
spleen CD8α+ DCs of mice reconstituted with 80% Cd11cCre+/Irf8flox/flox + 20% Clec9a +/+ bone marrow 
(CD8α+ DC-Cont), but markedly decreased in purified spleen CD8α+ DCs of mice reconstituted with 80% 
Cd11cCre+/Irf8flox/flox + 20% Clec9a -/- bone marrow (CD8α+ DC- Clec9a -/-) (Figure 4B). As expected, 
DNGR1 was barely expressed in purified CD8α- DCs from spleens of both groups of mice (Figure 4B). 
Reconstitution of spleen DCs, and more particularly CD8α+ DCs, was similar between the 2 groups of mice 
(Supplementary Figure VIC). 
 
Remarkably, the selective absence of DNGR1 in CD8α+ DCs significantly decreased plaque size 
(p=0.04) (Figure 4C and D), despite no change in plasma cholesterol levels (6.69±0.25 g/L vs 6.44±0.31 
g/L, p=0.46). Moreover, macrophage and T cell infiltration within the plaques were significantly decreased 
in the absence of DNGR1 in CD8α+ DCs, indicating that the expression of DNGR1 in CD8α+ DCs is 
required to mediate its pro-atherogenic effects (Supplementary Figure VII A and Figure 5A and B). 
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DNGR1 has previously been shown to induce CD8+ T-cell responses against dying cells 30. However, we 
found no differences in spleen CD8+ T-cell percentage or activation between the 2 groups of mice 
(Supplementary Fig. VII B), suggesting the involvement of other mechanisms. 
 
Interestingly, as in the total DNGR1-deficiency model, the specific deletion of DNGR1 in CD8α+ 
DCs led to a marked increase of IL10 expression in those cells (Supplementary Fig.VIIC) but also more 
generally in the spleen (Figure 5C), showing that DNGR1 specifically expressed by CD8α+ DCs plays a 
major role in the regulation of IL10. DNGR1 was also detected in CD45+ cells purified from atherosclerotic 
plaque aorta (Supplementary Fig. VIIIA), suggesting potential local effects. We also found higher Il10 
mRNA levels in aortas of mice with DNGR1 deletion in CD8α+ DCs compared to controls, without 
significant changes of Tnfα, Il6 and Tgfβ expression (Supplementary Fig. VIIIB). 
 
The expression of Il10 in CD8α+ DCs and DCs in general was relatively weak, which suggests that 
DNGR1 deficiency in CD8α+ DCs likely increased IL10 expression in other cell types. Accordingly, it was 
previously shown that IL10, and particularly DC-derived IL10 promoted IL10-producing T regulatory (Tr1) 
cells 31, 32. In this regard, we found that co-culture of splenic CD8α+ DCs purified from Il10-/- mice with 
Il10+/+ CD3+ T cells resulted in a significantly lower IL10 production as compared with the co-culture of 
Il10+/+ CD8α+ DCs with Il10+/+ CD3+ T cells, further highlighting the importance of CD8α+ DC-derived IL-
10 to stimulate IL10 production by T cells (Supplementary Figure IXA). Furthermore, co-culture of 
DNGR1-deficient CD8α+ DCs with CD3+ T cells significantly increased IL10 production by T cells without 
significant changes of IFNγ or IL17 (Supplementary Figure IXB-D). In line with these results, the selective 
absence of DNGR1 in CD8α+ DCs significantly increased IL10 expression in T-CD4+ cells in vivo (Figure 
5D), suggesting a specific bystander effect of DNGR1 expressed in CD8α+ DCs on the regulation of IL10 
production by CD4+ cells. Of note, DNGR1 in CD8α+DCs did not affect the levels of T regulatory cells 
(CD4+CD25+FOXP3+) (Supplementary Figure XA).  
 
To directly test the specific role of IL10 expression in CD8α+ DCs in the presence or absence of 
DNGR1, we irradiated and transplanted Ldlr-/- mice with 8:2 bone marrow from Cd11cCre+/Irf8flox/flox (80%) 
mice, mixed with 20% of bone marrow from either control (n=8), Clec9a -/- (n=9) Il10-/- (n=8) or Clec9a-/-
Il10-/- (n=9 ) mice. Then, the mice were put on HFD during 7 weeks. As shown in Figure 6A-D, specific 
IL10 deletion in CD8α+ DC abrogated the atheroprotection observed in absence of DNGR1 in this cell type, 
without any significant change of plasma cholesterol levels. This was associated with the inability of Clec9a 
deficiency to increase IL10 production by splenocytes (Figure 6E). Furthermore, co-culture of CD8α+ DCs 
from each group with wild-type CD4+ T cells showed that CD8α+ DCs promoted increased IL10 production 
by T cells in the absence of DNGR-1, which was dependent on IL10 expression in CD8α+ DC 
(Supplementary Figure XB), and most likely IL10 receptor signaling in CD4+ T cells (Supplementary 
Figure XC).  
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DISCUSSION 
 
Accumulation of apoptotic cells or debris during the development of atherosclerosis promotes 
inflammation, and contributes to plaque growth and thrombosis upon plaque rupture 5, 33.  We recently 
showed that C-type lectin receptor 4e (CLEC4e), known to be involved in the sensing of necrotic cores, 
promoted atherosclerosis through induction of endoplasmic reticulum stress-dependent macrophage 
proliferation, inflammation, and foam cell formation34. However, other C-type lectin receptors could 
recognize necrotic cores, and stimulate inflammation and plaque progression. 
 
Our findings provide in vivo and in vitro evidence that DNGR1, known to be involved in the sensing 
and presentation of antigens derived from necrotic cells12, is pro‐atherogenic, and its deletion in both Ldlr-
/- and Apoe-/- mouse models promotes an anti-inflammatory response and deactivates important pro-
atherogenic mechanisms. We have identified a new DNGR1-regulated IL10 pathway that controls vascular 
inflammation, and substantially impacts lesion development. DNGR1 deficiency inhibited macrophage and 
T cell infiltration within the plaques and up-regulated Tgfb and Il10, two major anti-inflammatory and anti-
atherogenic genes 2, 25. Intriguingly, the atheroprotective effect of DNGR1 deletion was already observed 
at the early stages of atherosclerosis (5 or 7 weeks of HFD) when plaques were still relatively small and 
apoptotic cell death was barely detectable. Even though we cannot rule out the possibility that DNGR1 was 
activated by some necrotic debris, it is likely that other PRRs, including TLRs, were activated during 
atherosclerosis 35 and interacted with DNGR1 signaling to activate inflammatory pathways. In agreement 
with this, our results showed that the absence of DNGR1 in splenocytes increased the production of the 
anti-inflammatory factor IL10 following TLR4 stimulation.  
 
After 13 weeks of HFD, we no longer observed differences in plaque size in the absence of DNGR1, 
despite the presence of necrotic cores. Also, the atheroprotection observed in absence of DNGR1 in Apoe-
/- mice fed with chow diet was abrogated when the mice were put on HFD. We believe that this was due to 
reduced Clec9a expression caused by the very high plasma cholesterol levels, as indicated by our in vitro 
experiments showing reduced CLEC9a expression by CD8α+DCs in the presence of high cholesterol. In 
agreement with this, we found that DNGR1 deletion was still atheroprotective in mice deficient for Mfge8, 
which exhibited after only 7 weeks of HFD (moderate hypercholesterolemia) increased accumulation of 
apoptotic/necrotic debris, and plaques as large as those found in Mfge8+/+ mice after 13 weeks of HFD 
(severe hypercholesterolemia). In addition, previous studies showed that T cells become dispensable for 
atherosclerosis development after prolonged and severe hypercholesterolemia 36, 37. More recently, Tsiaoui 
et al. reported that when Apoe-/- mice were fed a chow diet for 35 weeks, lesions were approximately the 
same size as after 12 weeks of HFD. Yet, T-bet deficient Apoe-/- mice, in which T cells are unable to 
differentiate into a Th1 phenotype, exhibited fewer plaques compared with immunocompetent Apoe-/- mice 
after 35 weeks of chow diet, while T-bet deficiency had no athero-protective effects in Apoe-/- mice fed a 
HFD for 12 weeks 38. As our data suggest that the protective effects of DNGR1 deletion are dependent on 
T cells, this may explain why the athero-protective effect is lost at very high plasma cholesterol levels. 
 
In agreement with our hypothesis of a role for DNGR1 in adaptive immune responses, earlier 
studies showed a restricted DNGR1 expression in CD8α+ DCs 12, 39. However, existing reports about the 
role of CD8α+ DCs in atherosclerosis are contradictory. One study used FMS-like tyrosine kinase (flt3)-/- 
Ldlr-/- double deficient mice, which displayed marked depletion of CD8α+ DCs, suggested a pro-atherogenic 
role of CD8α+ DCs 28. However, flt3-/- mice are also deficient for many other conventional DC subtypes. 
Moreover, in contrast to those results, atherosclerotic plaque formation and stability were not altered in 
chimeric Ldlr-/- mice transplanted with bone marrow from Basic leucine zipper transcription factor ATF-
like 3 (Batf3)-deficient mice that lack the CD8α+ DC subset, compared to Ldlr-/- mice transplanted with a 
control bone marrow 29. Our study differs from the previous ones in that we report on the deletion of a 
specific PRR selectively expressed by CD8α+ DCs, while preserving the other functions of this DC subset. 
Our present results clearly indicate that the specific deletion of DNGR1 in CD8α+ DCs promotes 
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atherosclerosis, identifying a previously unrecognized pro-atherogenic function of CD8α+ DCs in the 
development of atherosclerosis.  
DNGR1 stimulation in CD8α+ DCs has been previously shown to mediate cross-presentation of 
dead-cell-associated antigens leading to CD8+ T cell activation 11, 40. Thus, we expected that DNGR1 
expressed in CD8α+ DCs under conditions of hyperlipidemia would lead to CD8+ T cell activation. 
However, our results showed no significant changes in spleen CD8+ T cell count or activation between 
control and DNGR1-deficient mice, suggesting that cross-presentation may not be the main mechanism 
accounting for DNGR1-mediated pro-atherogenic effects. In addition, the role of CD8+ T cells and cross-
presentation in atherosclerosis is still debated 29, 41-43. Interestingly, we found that DNGR1 deletion in 
CD8α+ DCs increased the expression of the anti-inflammatory and anti-atherogenic IL10 in spleens, 
suggesting the involvement of this cytokine in the observed athero-protective effects. Noteworthy, spleen 
CD8α+ DCs purified from mice reconstituted with DNGR1 deficient CD8α+ DCs showed a significantly 
higher IL10 expression compared with control CD8α+ DCs. Yet, IL10 expression by CD8α+ DCs was weak, 
suggesting an additional impact of DNGR1 deficiency in CD8α+ DCs on IL10 expression in other cell 
types. In agreement with this, we found that the absence of DNGR1 in CD8α+ DCs led to increased IL10 
(but not IL17 nor IFNγ) production by CD4+ T cells, suggesting the induction of an anti-inflammatory and 
anti-atherogenic T cell response. 
Our findings point to an important role of IL10 as the main atheroprotective factor in the absence 
of DNGR1. First, IL10 expression was up-regulated at 5 and 7 weeks of high fat diet in the absence of 
DNGR1. However, after 13 weeks of high diet, when no difference of plaque size was observed, IL10 
expression remained unchanged in the absence of DNGR1. Moreover, double deficiency in DNGR1 and 
IL10, specifically in CD8α+ DCs completely abrogated the protective effects of DNGR1 deletion. The 
mechanisms leading to an increase of IL10 in the absence of DNGR1 are still unknown and will require 
further investigation. One likely mechanism is that interaction between TLRs and DNGR1 signaling 
modulates IL10 production through the SYK pathway 10, 11, 44, 45.  
In conclusion, our results identify a pro-atherogenic role for the necrotic cell sensor DNGR1 
through the regulation of IL10 production, and suggest a new potential therapeutic target to combat 
atherosclerosis. 
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FIGURE LEGENDS 
 
Figure 1: DNGR1 deletion in bone marrow protects against atherosclerosis A) Plasma cholesterol 
levels in 20 week-old male Apoe-/- (n=10) and male Apoe-/- Clec9a -/-(n=13) put on chow diet during 20 
weeks. B-C) Representative photomicrographs and quantification of lesion size in aortic sinus of male 
Apoe-/- (n=10) and male Apoe-/- Clec9a -/- mice (n=13) (D-E) Representative photomicrographs and 
quantification of lesion size in Ldlr-/- mice reconstituted with either control (Clec9a +/+  Ldlr-/-) or Clec9a 
-/- (Clec9a -/-  Ldlr-/-) bone marrow after 5 weeks (control (n=7) and Clec9a -/- (n=8)) or 7 weeks (control 
(n=12) and Clec9a -/- (n=16)) or 13 weeks (control (n=8) and Clec9a -/- (n=9)) of high fat diet (HFD). F) 
Representative photomicrographs and quantification of lesion size in the thoracic aorta of reconstituted with 
either control (Clec9a +/+  Ldlr-/- (n=12)) or Clec9a -/- (Clec9a -/-  Ldlr-/- (n=16)) bone marrow after 7 
weeks of HFD. Mean values  SEM are shown. * P<0.05, **P<0.001, ***P<0.0001 
 
Figure 2: DNGR1 deletion protects against vascular inflammation. A-B) Representative 
photomicrographs and quantitative analysis of lesional T cell infiltration in Ldlr-/- mice reconstituted with 
either Control (n=12) and Clec9a -/- (n=16) bone marrow after 7 weeks or Control (n=8) and Clec9a -/- (n=9) 
after 13 weeks of high fat diet (HFD). Plaque (P) and Media (M) are indicated. The results showed a 
significant decrease of T cells % (CD3 area: plaque area) in absence of DNGR1 after 7 weeks but not after 
13 weeks of HFD. C) Clec9a, Tgf-β and Il-10 mRNA in spleens of Ldlr-/- mice transplanted with Cont (n=7) 
or Clec9a -/- (n=9) bone marrow after 7 weeks of HFD. The results show a significant increase of Tgf- β 
and Il-10 expression in absence of DNGR1. Mean values  SEM are shown. *P<0.05, **P<0.001, 
***P<0.0001 
 
Figure 3: Il10 deficiency abrogates athero-protection in DNGR1-deficient mice. A-B) Representative 
photomicrographs and quantification of lesion size in the aortic sinus of lethally-irradiated male Ldlr-/- mice 
reconstituted with bone marrow from Clec9a+/+ (n=4) or Clec9a-/- (n=5) or Il10-/- (n=6) or Clec9a -/-Il10-/- 
(n=7) mice after 7 weeks of high fat diet (HFD). C-E) Representative photomicrographs and quantitative 
analysis of necrotic cores, lesional macrophage and T cell infiltration in Ldlr-/- mice reconstituted with either 
Il10-/- (n=6) and Clec9a -/-Il10-/- (n=7) bone marrow after 7 weeks of HFD. The results show the importance 
of Il-10 in DNGR1-mediated pro-atherogenic effects. Results were obtained after 4 weeks of recovery from 
bone marrow transplantation followed by 7 weeks on a HFD. Mean values  SEM are shown. *P<0.05, 
**P<0.001, ***P<0.0001.  
 
Figure 4: DNGR1 deletion in CD8α+DCs protects against atherosclerosis. A) Representative example 
and quantitative analysis of flow cytometry-donor origin defined as CD45.1 % and CD45.2 % of spleen 
cells from chimeric Ldlr-/- mice transplanted with bone marrow mix (2:8) from control (CD45.1) (n=7) or 
Clec9a -/- (n=8) bone marrow cells mixed with Cd11cCre+/Irf8flox/flox (CD45.2) bone marrow. After bone 
marrow reconstitution, the mice were put on a HFD during 7 weeks. The results show that the majority of 
spleen cells (80%) originates from CD45.2 bone marrow. B) Clec9a mRNA in pooled purified CD8α+DCs 
isolated from either control group (CD8α+DC-Cont, n=7) or DNGR1-deficient CD8α+DC group 
(CD8α+DC-Clec9a -/-, n=8). (C-D) Representative photomicrographs and quantification of lesion size in 
aortic sinus of chimeric Ldlr-/- mice transplanted with 2:8 mix of bone marrow from control (CD45.1) (n=7) 
or Clec9a -/- (n=8) bone marrow cells mixed with Cd11cCre+/Irf8flox/flox (CD45.2) bone marrow. The results 
show that the deletion of DNGR1 in CD8α+DCs protects against atherosclerosis. Mean values  SEM are 
shown. P<0.05, **P<0.001, ***P<0.0001.  
 
Figure 5: DNGR1 deletion in CD8α+DCs alleviates inflammation in atherosclerosis. A-B) 
photomicrographs and quantitative analysis of lesional T cell infiltration in Ldlr-/- mice reconstituted with 
either control group (CD8α+DC-Cont, n=7) or DNGR1-deficient CD8α+DC group (CD8α+DC-Clec9a -/-, 
n=8) after 7 weeks of HFD. Plaque (P) and media (M) are indicated. C) Il-10 mRNA in spleens of control 
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group (CD8α+DC-Cont, n=7) or DNGR1-deficient CD8α+DC group (CD8α+DC-Clec9a -/-, n=8). D) 
Representative examples and quantitative analysis of flow cytometry-based intracellular staining of IL-10 
gated on CD4+ cells from the DNGR1-deficient CD8α+DCs (n=8) compared to control-CD8α+DCs (n=7) 
groups of mice. The results show the importance of DNGR1 in CD8α+DC-mediated pro-atherogenic effects. 
Mean values  SEM are shown. *P<0.05, **P<0.001, ***P<0.0001.  
Figure 6: IL-10 deletion abrogates protective effects of DNGR-1 absence in CD8α+DCs. A-B) 
Representative photomicrographs and quantification of lesion size in aortic sinus C) plasma cholesterol in 
chimeric Ldlr-/- mice transplanted with 2:8 mix of bone marrow from control (n=8) or Clec9a -/- (n=9) or Il-
10-/- (n=8) or Clec9a-/-Il-10-/- (n=9 ) bone marrow cells mixed with Cd11cCre+/Irf8flox/flox bone marrow after 
7 wks of high fat diet (HFD).D) Clec9a and Il-10 mRNA in pooled purified CD8α+DCs isolated from either 
control group (CD8α+DC-Cont, n=8) or DNGR1-deficient CD8α+DC group (CD8α+DC-Clec9a -/-, n=9) or 
IL-10-deficient CD8α+DC group (CD8α+DC-Il-10 -/-, n=8) or DNGR-1/IL-10-deficient CD8α+DC group 
(CD8α+DC-Clec9a-/-Il-10 -/-, n=9). E)  IL-10 production by anti-CD3 (5ug/ml) and anti-CD28 (1 ug/ml) 
stimulated splenocytes from either CD8α+DC-Cont (n=8) or CD8α+DC-Clec9a -/- (n=9) or CD8α+DC-Il-10
-/- (n=8) or CD8α+DC-Clec9a-/-Il-10 -/- (n=9), in presence of LPS (1µg/ml). The results show that the deletion 
of IL-10 abrogates the protective effects of DNGR1 deletion in CD8α+DCs. Mean values  SEM are shown. 
P<0.05, **P<0.001, ***P<0.0001 
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NOVELTY AND SIGNIFICANCE 
What Is Known? 
 Advanced atherosclerotic plaques are characterized by an increase i necrotic cells.
 A necrotic core increases plaque instability.
 The DNGR1 (Dendritic cell NK lectin Group Receptor-1) is involved in sensing necrotic cells.
What New Information Does This Article Contribute? 
  The DNGR1, specifically expressed by a subtype of dendritic cells (CD8α+DCs), has pro-
inflammatory and pro-atherogenic effects that depend on interleukin 10 (IL-10).
 A new role of DNGR1 in regulating vascular inflammation and atherosclerosis, making it a
potential target that could be blocked to promote plaque stabilization.
Accumulation of necrotic debris increases inflammation in atherosclerotic lesions and has been associated 
with higher susceptibility to plaque rupture. However, the mechanisms that contribute to necrosis-induced 
inflammation during atherogenesis remain unclear. DNGR1 is a sensor of necrotic cells that is preferentially 
expressed in a subtype of dendritic cells (CD8α+DCs). We have shown that in a context of moderate 
hypercholesterolemia the total bone marrow and CD8α+DC-specific DNGR1 deletion decreased the 
infiltration of T lymphocytes and macrophages within lesions as well as plaque size. Mechanistically, the 
absence of DNGR1 led to increased expression of Il-10 in CD8α+DCs, which also appeared to impact the 
production of IL-10 by CD4+ cells. Moreover, deletion of Il-10 in CD8α+DCs abolished the 
atheroprotective effects of  DNGR1 deficiency.  Further studies are required to determine whether increased 
DNGR1 is associated with the formation of thin-cap fibroatheromatous lesions in humans and whether 
blockage of this protein would promote plaque stabilization.  






